234 related articles for article (PubMed ID: 16960554)
41. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
42. Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.
Tamura K; Fujiyuki T; Moritoh K; Akimoto H; Iizuka K; Sato H; Asano K; Yoneda M; Kai C
Sci Rep; 2023 Oct; 13(1):18168. PubMed ID: 37875555
[TBL] [Abstract][Full Text] [Related]
43. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E
Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744
[TBL] [Abstract][Full Text] [Related]
44. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Schroeder M; Puri RK; Russell SJ; Galanis E
Mol Ther; 2008 Sep; 16(9):1556-64. PubMed ID: 18665158
[TBL] [Abstract][Full Text] [Related]
46. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
47. Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration.
Condack C; Grivel JC; Devaux P; Margolis L; Cattaneo R
J Infect Dis; 2007 Aug; 196(4):541-9. PubMed ID: 17624839
[TBL] [Abstract][Full Text] [Related]
48. The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
Ammour Y; Ryabaya O; Shchetinina Y; Prokofeva E; Gavrilova M; Khochenkov D; Vorobyev D; Faizuloev E; Shohin I; Zverev VV; Svitich O; Nasedkina T
Viruses; 2020 Feb; 12(2):. PubMed ID: 32033013
[TBL] [Abstract][Full Text] [Related]
49. Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines.
Terao-Muto Y; Yoneda M; Seki T; Watanabe A; Tsukiyama-Kohara K; Fujita K; Kai C
Antiviral Res; 2008 Dec; 80(3):370-6. PubMed ID: 18812191
[TBL] [Abstract][Full Text] [Related]
50. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.
Amagai Y; Fujiyuki T; Yoneda M; Shoji K; Furukawa Y; Sato H; Kai C
Sci Rep; 2016 Apr; 6():24572. PubMed ID: 27090874
[TBL] [Abstract][Full Text] [Related]
52. Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer.
Zhao D; Chen P; Yang H; Wu Y; Zeng X; Zhao Y; Wen Y; Zhao X; Liu X; Wei Y; Li Y
Oncol Rep; 2013 Jan; 29(1):199-204. PubMed ID: 23129111
[TBL] [Abstract][Full Text] [Related]
53. Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.
Zhang SC; Wang WL; Cai WS; Jiang KL; Yuan ZW
BMC Cancer; 2012 Sep; 12():427. PubMed ID: 23009685
[TBL] [Abstract][Full Text] [Related]
54. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.
Rennick LJ; de Vries RD; Carsillo TJ; Lemon K; van Amerongen G; Ludlow M; Nguyen DT; Yüksel S; Verburgh RJ; Haddock P; McQuaid S; Duprex WP; de Swart RL
J Virol; 2015 Feb; 89(4):2192-200. PubMed ID: 25473055
[TBL] [Abstract][Full Text] [Related]
55. Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma.
Parrula C; Fernandez SA; Zimmerman B; Lairmore M; Niewiesk S
J Gen Virol; 2011 Jun; 92(Pt 6):1458-1466. PubMed ID: 21325484
[TBL] [Abstract][Full Text] [Related]
56. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.
Hallak LK; Merchan JR; Storgard CM; Loftus JC; Russell SJ
Cancer Res; 2005 Jun; 65(12):5292-300. PubMed ID: 15958576
[TBL] [Abstract][Full Text] [Related]
57. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
58. An immune competent mouse model for the characterization of recombinant measles vaccines.
Marty RR; Knuchel MC; Morin TN; Naim HY
Hum Vaccin Immunother; 2015; 11(1):83-90. PubMed ID: 25483519
[TBL] [Abstract][Full Text] [Related]
59. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma.
Lal S; Raffel C
Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698
[TBL] [Abstract][Full Text] [Related]
60. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
